In the Literature

Lost Earnings from Cancer-Related Deaths Cost the United States $94 Billion in 2015

October 2019, Vol 10, No 5 - In the Literature

In a new analysis, researchers examined the estimated cost of lost earnings that resulted from cancer-related deaths in the United States, nationally and by state. This study is not the first to examine the economic burden of cancer deaths in the United States. However, the study does provide contemporary estimates of person-years of life lost (PYLL) as a result of cancer deaths and the associated lost earnings at the national and state levels for all cancers combined (Islami F, et al. JAMA Oncol. 2019 Jul 3 [Epub ahead of print].). [ Read More ]

Long-Term Outcomes Affect Cost-Effectiveness of CAR T-Cell Therapy for DLBCL

August 2019, Vol 10, No 4 | Payers’ Perspectives In Oncology: ASCO 2019 Highlights - In the Literature, Lymphoma

The 2 chimeric antigen receptor (CAR) T-cell therapies available so far—axicabtagene ciloleucel (Yescarta) and tisagenlecleucel (Kymriah)—may be considered cost-effective treatments for adults with diffuse large B-cell lymphoma (DLBCL), depending on the long-term outcomes of these patients, according to a recent cost-effective analysis (Lin JK, et al. J Clin Oncol. 2019 Jun 3. Epub ahead of print). [ Read More ]

New Triple-Drug Regimen for Newly Diagnosed Patients with Multiple Myeloma

August 2019, Vol 10, No 4 | Payers’ Perspectives In Oncology: ASCO 2019 Highlights - In the Literature, Multiple Myeloma

Until recently, patients with newly diagnosed multiple myeloma who are ineligible for autologous stem-cell transplantation (ASCT), the multiagent regimen with lenalidomide (Revlimid) and dexamethasone was the standard of care. Results of the prespecified interim analysis of the MAIA trial demonstrated the benefit of adding daratumumab (Darzalex) to this combination therapy (Facon T, et al. N Engl J Med. 2019;380:2104-2115). Based on the results of this study, on July 1, 2019, the FDA approved this triple-drug regimen for use in this patient population. [ Read More ]

Ibrutinib Superior to Standard Chemoimmunotherapy in Older Patients with CLL

January/February 2019, Vol 10, No 1 | Payers’ Perspectives In Oncology: ASH 2018 Highlights - In the Literature, Leukemia

Chemoimmunotherapy with chlor­ambucil plus obinutuzumab or bendamustine plus rituximab is standard frontline treatment for older patients with chronic lymphocytic leukemia (CLL). However, chemoimmunotherapy is associated with toxic effects, and the risk increases with age. For patients with CLL, frontline ibrutinib monotherapy is widely used in clinical practice. The benefit of this Bruton’s tyrosine kinase (BTK) inhibitor versus standard chemoimmunotherapy remains a critical consideration, which led researchers to conduct a head-to-head phase 3 study to evaluate the efficacy of ibrutinib, either alone or in combination with rituximab, relative to chemoimmunotherapy. [ Read More ]

Olaparib Maintenance Extends Progression-Free Survival in Advanced Ovarian Cancer

January/February 2019, Vol 10, No 1 | Payers’ Perspectives In Oncology: ASH 2018 Highlights - In the Literature, Ovarian Cancer

Currently, there are limited therapies to prevent or delay recurrence in advanced ovarian cancer, with approximately 70% of patients having a recurrence within 3 years. The effectiveness of olaparib, an oral poly (ADP-ribose) polymerase inhibitor, in relapsed disease has been well-established; however, its benefit as a maintenance therapy in newly diagnosed advanced ovarian cancer is uncertain. In a recent study, researchers evaluated the efficacy of upfront maintenance therapy with olaparib in patients with newly diagnosed, advanced BRCA-positive ovarian cancer. [ Read More ]

Sunitinib After Nephrectomy Benefits Some Patients with Advanced Kidney Cancer

October 2018, Vol 9, No 3 - In the Literature

Nephrectomy has been the standard of care in metastatic renal-cell carcinoma for 20 years. However, its role in treating patients with advanced disease in the era of targeted therapy has been brought into question. In the CARMENA study, researchers assessed the benefit of initial nephrectomy followed by targeted therapy with sunitinib (Sutent) in patients with metastatic kidney cancer versus the benefits provided by su­nitinib monotherapy. [ Read More ]

Talazoparib, a New PARP Inhibitor, Shows Significant Benefit in Patients with Breast Cancer and BRCA Mutation

October 2018, Vol 9, No 3 - In the Literature

Talazoparib, an oral investigational poly (ADP-ribose) polymerase (PARP) inhibitor, is currently being evaluated in advanced breast cancer with BRCA mutation and other cancer types. Talaz­oparib’s dual mechanism of action has the potential to induce tumor cell death by blocking PARP enzyme activity and trapping PARP on the sites of DNA damage. [ Read More ]